克拉霉素治疗慢性阻塞性肺疾病急性加剧期50例  

The Efficacy of Clarithromycin in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases in 50 Cases

作　　者：王洪金[1] 魏清[1] 赵斯运[1] 

机构地区：[1]江苏省连云港市第一人民医院

出　　处：《医学理论与实践》2002年第2期141-143,共3页The Journal of Medical Theory and Practice

摘　　要：目的:对照观察口服克拉霉素与静注氨苄青霉素+舒巴坦钠治疗慢性阻塞性肺疾病(COPD)急性加剧期的疗效与不良反应。方法:将50例COPD急性加剧期患者随机分为2组,每组均为25例,治疗组口服克拉霉素0.5g,bid,对照组静注氨苄青霉素+舒巴坦钠1.5g,bid。结果:治疗组的有效率为88％,对照组的有效率为72％,不良反应发生率两组均为16％。结论:克拉霉素治疗COPD急性加剧期的临床疗效好,病原菌覆盖面广,使用方便。Objective:To compare the efficacy and side effect of clarithromycin and ampecillin-sulbactum in treatment of acute exacerbation of chronic obstructive pulmonary diseases (COPD).Methods:50 acute exacerbation patients of COPD were randomly and equally divided into two groups.The treatment grour) received 0.5g clarithromycin orally,bid,and the control group was given injection of 1.5g ampecillinsulbactum infusion intravenously, bid. Results: The total effective rate for clarithromycin and ampecillin-sulbactum groups was 90% and 78.8% , respectively, and the side effect rate wap 16% in both groups. Conclusion: Clarithromycin is an ideal agent for treatment of acute exacerbation of COPD with the advantages of convenience and broad anti-bacterial spectrum.

关 键 词：急性加剧期 克拉霉素 下呼吸道感染 慢性阻塞性肺病 治疗 

分 类 号：R563.05[医药卫生—呼吸系统]